- Home
- ZENV vs NVCT Comparison
ZENV vs NVCT Comparison
Compare ZENV & NVCT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ZENV | NVCT |
|---|---|---|
| Founded | 2005 | 2020 |
| Country | Brazil | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Medicinal Chemicals and Botanical Products |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 56.2M | 197.0M |
| IPO Year | 2021 | 2022 |
Fundamental Metrics
Financial Performance| Metric | ZENV | NVCT |
|---|---|---|
| Price | $1.07 | $7.93 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $15.33 |
| AVG Volume (30 Days) | 29.8K | ★ 102.5K |
| Earning Date | 03-16-2026 | 11-04-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $201,426,369.00 | N/A |
| Revenue This Year | $12.75 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 24.80 | N/A |
| 52 Week Low | $0.94 | $4.44 |
| 52 Week High | $3.03 | $11.52 |
Technical Indicators
Market Signals| Indicator | ZENV | NVCT |
|---|---|---|
| Relative Strength Index (RSI) | 29.79 | 71.56 |
| Support Level | $0.94 | $6.47 |
| Resistance Level | $1.27 | $7.77 |
| Average True Range (ATR) | 0.08 | 0.40 |
| MACD | -0.01 | 0.12 |
| Stochastic Oscillator | 36.36 | 92.07 |
Price Performance
Historical ComparisonAbout ZENV Zenvia Inc.
Zenvia Inc provides a platform that enables companies to create journeys for their end customers across a variety of channels. The company operates in two reportable segments namely CPaaS and SaaS. It has a geographic presence in Brazil, the USA, Argentina, Mexico, and Others. The company generates the majority of its revenue from Brazil.
About NVCT Nuvectis Pharma Inc.
Nuvectis Pharma Inc is a biopharmaceutical company. The company is engaged in the development of innovative precision medicines for the treatment of serious conditions of unmet medical needs in oncology. It operates with one segment, focused on the development of novel targeted small molecule therapeutics for the treatment of cancer in genetically defined patient populations. Its pipeline products include NXP800, NXP900.